Skip to main content

11.02.2024 | Progress in Hematology

Dysregulated hemostasis in acute promyelocytic leukemia

verfasst von: Yohei Hisada

Erschienen in: International Journal of Hematology

Einloggen, um Zugang zu erhalten

Abstract

Acute promyelocytic leukemia (APL) is associated with a high incidence of early death, which occurs within 30 days of diagnosis. The major cause of early death in APL is severe bleeding, particularly intracranial bleeding. Although APL is known to be associated with activation of coagulation, hyperfibrinolysis, and thrombocytopenia, the precise mechanisms that cause bleeding have not yet been elucidated. I propose that a combination of four pathways may contribute to bleeding in APL: (1) tissue factor, (2) the urokinase plasminogen activator/urokinase plasminogen activator receptor, (3) the annexin A2/S100A100/tissue plasminogen activator, and (4) the podoplanin/C-type lectin-like receptor 2. A better understanding of these pathways will identify new biomarkers to determine which APL patients are at high risk of bleeding and allow the development of new treatments for APL-associated bleeding.
Literatur
1.
Zurück zum Zitat Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975–2008. Cancer. 2012;118(23):5811–8.PubMedCrossRef Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975–2008. Cancer. 2012;118(23):5811–8.PubMedCrossRef
3.
Zurück zum Zitat Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74(3):423–31.PubMedCrossRef Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74(3):423–31.PubMedCrossRef
4.
Zurück zum Zitat Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993;82(11):3241–9.PubMedCrossRef Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993;82(11):3241–9.PubMedCrossRef
5.
Zurück zum Zitat Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, et al. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol. 1997;40:30–5.CrossRef Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, et al. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol. 1997;40:30–5.CrossRef
6.
Zurück zum Zitat Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021–8.PubMedCrossRef Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021–8.PubMedCrossRef
7.
Zurück zum Zitat Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group Blood. 1999;94(4):1192–200.PubMed Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group Blood. 1999;94(4):1192–200.PubMed
8.
Zurück zum Zitat Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009;23(12):2248–58.PubMedCrossRef Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009;23(12):2248–58.PubMedCrossRef
9.
Zurück zum Zitat Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110(1):59–66.PubMedCrossRef Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110(1):59–66.PubMedCrossRef
10.
Zurück zum Zitat Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117(18):4716–25.PubMedCrossRef Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117(18):4716–25.PubMedCrossRef
11.
Zurück zum Zitat Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–305.PubMedCrossRef Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–305.PubMedCrossRef
12.
Zurück zum Zitat Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248–54.PubMedPubMedCentralCrossRef Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248–54.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97(1):133–6.PubMedPubMedCentralCrossRef McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97(1):133–6.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Mollgard L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128–34.PubMedCrossRef Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Mollgard L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128–34.PubMedCrossRef
15.
Zurück zum Zitat Lehmann S, Deneberg S, Antunovic P, Rangert-Derolf A, Garelius H, Lazarevic V, et al. Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997–2013. Leukemia. 2017;31(6):1457–9.PubMedCrossRef Lehmann S, Deneberg S, Antunovic P, Rangert-Derolf A, Garelius H, Lazarevic V, et al. Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997–2013. Leukemia. 2017;31(6):1457–9.PubMedCrossRef
16.
Zurück zum Zitat Xu F, Wang C, Yin C, Jiang X, Jiang L, Wang Z, et al. Analysis of early death in newly diagnosed acute promyelocytic leukemia patients. Medicine. 2017;96(51): e9324.PubMedPubMedCentralCrossRef Xu F, Wang C, Yin C, Jiang X, Jiang L, Wang Z, et al. Analysis of early death in newly diagnosed acute promyelocytic leukemia patients. Medicine. 2017;96(51): e9324.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Ho G, Li Q, Brunson A, Jonas BA, Wun T, Keegan THM. Complications and early mortality in patients with acute promyelocytic leukemia treated in California. Am J Hematol. 2018;93(11):E370–2.PubMedPubMedCentralCrossRef Ho G, Li Q, Brunson A, Jonas BA, Wun T, Keegan THM. Complications and early mortality in patients with acute promyelocytic leukemia treated in California. Am J Hematol. 2018;93(11):E370–2.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Abedin S, Altman JK. Acute promyelocytic leukemia: preventing early complications and late toxicities. Hematology Am Soc Hematol Educ Program. 2016;2016(1):10–5.PubMedPubMedCentralCrossRef Abedin S, Altman JK. Acute promyelocytic leukemia: preventing early complications and late toxicities. Hematology Am Soc Hematol Educ Program. 2016;2016(1):10–5.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Hoyle CF, Swirsky DM, Freedman L, Hayhoe FG. Beneficial effect of heparin in the management of patients with APL. Br J Haematol. 1988;68(3):283–9.PubMedCrossRef Hoyle CF, Swirsky DM, Freedman L, Hayhoe FG. Beneficial effect of heparin in the management of patients with APL. Br J Haematol. 1988;68(3):283–9.PubMedCrossRef
20.
Zurück zum Zitat Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood. 1988;71(3):690–6.PubMedCrossRef Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood. 1988;71(3):690–6.PubMedCrossRef
21.
Zurück zum Zitat Chang H, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH, et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol. 2012;88(4):321–8.PubMedCrossRef Chang H, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH, et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol. 2012;88(4):321–8.PubMedCrossRef
22.
Zurück zum Zitat Higuchi T, Toyama D, Hirota Y, Isoyama K, Mori H, Niikura H, et al. Disseminated intravascular coagulation complicating acute lymphoblastic leukemia: a study of childhood and adult cases. Leuk Lymphoma. 2005;46(8):1169–76.PubMedCrossRef Higuchi T, Toyama D, Hirota Y, Isoyama K, Mori H, Niikura H, et al. Disseminated intravascular coagulation complicating acute lymphoblastic leukemia: a study of childhood and adult cases. Leuk Lymphoma. 2005;46(8):1169–76.PubMedCrossRef
23.
Zurück zum Zitat Dixit A, Chatterjee T, Mishra P, Kannan M, Choudhry DR, Mahapatra M, et al. Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy. Clin Appl Thromb/Hemost Off J Int Acad Clin Appl Thromb/Hemost. 2007;13(3):292–8.CrossRef Dixit A, Chatterjee T, Mishra P, Kannan M, Choudhry DR, Mahapatra M, et al. Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy. Clin Appl Thromb/Hemost Off J Int Acad Clin Appl Thromb/Hemost. 2007;13(3):292–8.CrossRef
24.
Zurück zum Zitat Uchiumi H, Matsushima T, Yamane A, Doki N, Irisawa H, Saitoh T, et al. Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. Int J Hematol. 2007;86(2):137–42.PubMedCrossRef Uchiumi H, Matsushima T, Yamane A, Doki N, Irisawa H, Saitoh T, et al. Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. Int J Hematol. 2007;86(2):137–42.PubMedCrossRef
25.
Zurück zum Zitat Libourel EJ, Klerk CPW, van Norden Y, de Maat MPM, Kruip MJ, Sonneveld P, et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood. 2016;128(14):1854–61.PubMedCrossRef Libourel EJ, Klerk CPW, van Norden Y, de Maat MPM, Kruip MJ, Sonneveld P, et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood. 2016;128(14):1854–61.PubMedCrossRef
26.
Zurück zum Zitat Sletnes KE, Godal HC, Wisloff F. Disseminated intravascular coagulation (DIC) in adult patients with acute leukaemia. Eur J Haematol. 1995;54(1):34–8.PubMedCrossRef Sletnes KE, Godal HC, Wisloff F. Disseminated intravascular coagulation (DIC) in adult patients with acute leukaemia. Eur J Haematol. 1995;54(1):34–8.PubMedCrossRef
27.
Zurück zum Zitat Nur S, Anwar M, Saleem M, Ahmad PA. Disseminated intravascular coagulation in acute leukaemias at first diagnosis. Eur J Haematol. 1995;55(2):78–82.PubMedCrossRef Nur S, Anwar M, Saleem M, Ahmad PA. Disseminated intravascular coagulation in acute leukaemias at first diagnosis. Eur J Haematol. 1995;55(2):78–82.PubMedCrossRef
28.
Zurück zum Zitat Kwaan HC. The unique hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost. 2014;40(3):332–6.PubMedCrossRef Kwaan HC. The unique hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost. 2014;40(3):332–6.PubMedCrossRef
29.
Zurück zum Zitat Ikezoe T. Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. Int J Hematol. 2014;100(1):27–37.PubMedCrossRef Ikezoe T. Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. Int J Hematol. 2014;100(1):27–37.PubMedCrossRef
30.
Zurück zum Zitat Grover SP, Mackman N. Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis. Arterioscler Thromb Vasc Biol. 2018;38(4):709–25.PubMedCrossRef Grover SP, Mackman N. Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis. Arterioscler Thromb Vasc Biol. 2018;38(4):709–25.PubMedCrossRef
31.
Zurück zum Zitat Hisada Y, Sachetto ATA, Mackman N (2022) Circulating tissue factor-positive extracellular vesicles and their association with thrombosis in different diseases. Immunol Rev. 2022;312(1):61-75.PubMedCrossRef Hisada Y, Sachetto ATA, Mackman N (2022) Circulating tissue factor-positive extracellular vesicles and their association with thrombosis in different diseases. Immunol Rev. 2022;312(1):61-75.PubMedCrossRef
32.
Zurück zum Zitat Dombret H, Scrobohaci ML, Ghorra P, Zini JM, Daniel MT, Castaigne S, et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia. 1993;7(1):2–9.PubMed Dombret H, Scrobohaci ML, Ghorra P, Zini JM, Daniel MT, Castaigne S, et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia. 1993;7(1):2–9.PubMed
33.
Zurück zum Zitat Tallman MS, Lefebvre P, Baine RM, Shoji M, Cohen I, Green D, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. Journal of thrombosis and haemostasis : JTH. 2004;2(8):1341–50.PubMedCrossRef Tallman MS, Lefebvre P, Baine RM, Shoji M, Cohen I, Green D, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. Journal of thrombosis and haemostasis : JTH. 2004;2(8):1341–50.PubMedCrossRef
34.
Zurück zum Zitat Falanga A, Iacoviello L, Evangelista V, Belotti D, Consonni R, D’Orazio A, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood. 1995;86(3):1072–81.PubMedCrossRef Falanga A, Iacoviello L, Evangelista V, Belotti D, Consonni R, D’Orazio A, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood. 1995;86(3):1072–81.PubMedCrossRef
35.
Zurück zum Zitat Dicke C, Amirkhosravi A, Spath B, Jimenez-Alcazar M, Fuchs T, Davila M, et al. Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study. Exp Hematol Oncol. 2015;4:22.PubMedPubMedCentralCrossRef Dicke C, Amirkhosravi A, Spath B, Jimenez-Alcazar M, Fuchs T, Davila M, et al. Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study. Exp Hematol Oncol. 2015;4:22.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Langer F, Spath B, Haubold K, Holstein K, Marx G, Wierecky J, et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol. 2008;87(6):451–7.PubMedCrossRef Langer F, Spath B, Haubold K, Holstein K, Marx G, Wierecky J, et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol. 2008;87(6):451–7.PubMedCrossRef
37.
Zurück zum Zitat Thaler J, Pabinger I, Sperr WR, Ay C. Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res. 2014;133(3):303–5.PubMedCrossRef Thaler J, Pabinger I, Sperr WR, Ay C. Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res. 2014;133(3):303–5.PubMedCrossRef
38.
Zurück zum Zitat Zhao H, Sun J, Yan L, Jin B, Hou W, Cao F, et al. Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study. Ann Hematol. 2021;100(6):1473–83.PubMedCrossRef Zhao H, Sun J, Yan L, Jin B, Hou W, Cao F, et al. Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study. Ann Hematol. 2021;100(6):1473–83.PubMedCrossRef
40.
Zurück zum Zitat Hisada Y, Kawano T, Archibald SJ, Welch JS, Reeves BN, Mackman N. Tissue factor activates the coagulation cascade in mouse models of acute promyelocytic leukemia. Blood Adv. 2023;7(18):5458–69.PubMedPubMedCentralCrossRef Hisada Y, Kawano T, Archibald SJ, Welch JS, Reeves BN, Mackman N. Tissue factor activates the coagulation cascade in mouse models of acute promyelocytic leukemia. Blood Adv. 2023;7(18):5458–69.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Passerini CG, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood. 1998;92(1):143–51.PubMedCrossRef Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Passerini CG, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood. 1998;92(1):143–51.PubMedCrossRef
42.
Zurück zum Zitat Marchetti M, Diani E, ten Cate H, Falanga A. Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography. Haematologica. 2012;97(8):1173–80.PubMedPubMedCentralCrossRef Marchetti M, Diani E, ten Cate H, Falanga A. Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography. Haematologica. 2012;97(8):1173–80.PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Welch JS, Klco JM, Varghese N, Nagarajan R, Ley TJ. Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice. Blood. 2011;117(8):2460–8.PubMedPubMedCentralCrossRef Welch JS, Klco JM, Varghese N, Nagarajan R, Ley TJ. Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice. Blood. 2011;117(8):2460–8.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 2004;25(8):450–5.PubMedCrossRef Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 2004;25(8):450–5.PubMedCrossRef
45.
Zurück zum Zitat Wang P, Zhang Y, Yang H, Hou W, Jin B, Hou J, et al. Characteristics of fibrinolytic disorders in acute promyelocytic leukemia. Hematology. 2018;23(10):756–64.PubMedCrossRef Wang P, Zhang Y, Yang H, Hou W, Jin B, Hou J, et al. Characteristics of fibrinolytic disorders in acute promyelocytic leukemia. Hematology. 2018;23(10):756–64.PubMedCrossRef
46.
Zurück zum Zitat Mustjoki S, Alitalo R, Stephens RW, Vaheri A. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy. Thromb Haemost. 1999;81(5):705–10.PubMedCrossRef Mustjoki S, Alitalo R, Stephens RW, Vaheri A. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy. Thromb Haemost. 1999;81(5):705–10.PubMedCrossRef
47.
Zurück zum Zitat Lavallee VP, Chagraoui J, MacRae T, Marquis M, Bonnefoy A, Krosl J, et al. Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. Leukemia. 2018;32(6):1349–57.PubMedCrossRef Lavallee VP, Chagraoui J, MacRae T, Marquis M, Bonnefoy A, Krosl J, et al. Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. Leukemia. 2018;32(6):1349–57.PubMedCrossRef
48.
Zurück zum Zitat Tapiovaara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors. Blood. 1994;83(7):1883–91.PubMedCrossRef Tapiovaara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors. Blood. 1994;83(7):1883–91.PubMedCrossRef
49.
Zurück zum Zitat Mustjoki S, Tapiovaara H, Siren V, Vaheri A. Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells. Leukemia. 1998;12(2):164–74.PubMedCrossRef Mustjoki S, Tapiovaara H, Siren V, Vaheri A. Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells. Leukemia. 1998;12(2):164–74.PubMedCrossRef
50.
Zurück zum Zitat Zheng PZ, Wang KK, Zhang QY, Huang QH, Du YZ, Zhang QH, et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA. 2005;102(21):7653–8.ADSPubMedPubMedCentralCrossRef Zheng PZ, Wang KK, Zhang QY, Huang QH, Du YZ, Zhang QH, et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA. 2005;102(21):7653–8.ADSPubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Saumet A, Vetter G, Bouttier M, Portales-Casamar E, Wasserman WW, Maurin T, et al. Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood. 2009;113(2):412–21.PubMedCrossRef Saumet A, Vetter G, Bouttier M, Portales-Casamar E, Wasserman WW, Maurin T, et al. Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood. 2009;113(2):412–21.PubMedCrossRef
52.
Zurück zum Zitat Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol. 1989;71(4):511–7.PubMedCrossRef Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol. 1989;71(4):511–7.PubMedCrossRef
53.
54.
Zurück zum Zitat Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29(1):17–24.PubMedCrossRef Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29(1):17–24.PubMedCrossRef
55.
Zurück zum Zitat Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340(13):994–1004.PubMedCrossRef Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340(13):994–1004.PubMedCrossRef
56.
Zurück zum Zitat O’Connell PA, Madureira PA, Berman JN, Liwski RS, Waisman DM. Regulation of S100A10 by the PML-RAR-alpha oncoprotein. Blood. 2011;117(15):4095–105.PubMedCrossRef O’Connell PA, Madureira PA, Berman JN, Liwski RS, Waisman DM. Regulation of S100A10 by the PML-RAR-alpha oncoprotein. Blood. 2011;117(15):4095–105.PubMedCrossRef
57.
Zurück zum Zitat Liu Y, Wang Z, Jiang M, Dai L, Zhang W, Wu D, et al. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res. 2011;35(7):879–84.PubMedCrossRef Liu Y, Wang Z, Jiang M, Dai L, Zhang W, Wu D, et al. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res. 2011;35(7):879–84.PubMedCrossRef
58.
Zurück zum Zitat Huang D, Yang Y, Sun J, Dong X, Wang J, Liu H, et al. Annexin A2–S100A10 heterotetramer is upregulated by PML/RARalpha fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocytic leukemia. Front Med. 2017;11(3):410–22.PubMedCrossRef Huang D, Yang Y, Sun J, Dong X, Wang J, Liu H, et al. Annexin A2–S100A10 heterotetramer is upregulated by PML/RARalpha fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocytic leukemia. Front Med. 2017;11(3):410–22.PubMedCrossRef
59.
Zurück zum Zitat Holloway RW, Thomas ML, Cohen AM, Bharadwaj AG, Rahman M, Marcato P, et al. Regulation of cell surface protease receptor S100A10 by retinoic acid therapy in acute promyelocytic leukemia (APL)(☆). Cell Death Dis. 2018;9(9):920.PubMedPubMedCentralCrossRef Holloway RW, Thomas ML, Cohen AM, Bharadwaj AG, Rahman M, Marcato P, et al. Regulation of cell surface protease receptor S100A10 by retinoic acid therapy in acute promyelocytic leukemia (APL)(☆). Cell Death Dis. 2018;9(9):920.PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Jacomo RH, Santana-Lemos BA, Lima AS, Assis PA, Lange AP, Figueiredo-Pontes LL, et al. Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia. Blood. 2012;120(1):207–13.PubMedCrossRef Jacomo RH, Santana-Lemos BA, Lima AS, Assis PA, Lange AP, Figueiredo-Pontes LL, et al. Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia. Blood. 2012;120(1):207–13.PubMedCrossRef
61.
Zurück zum Zitat Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood. 2019;134(22):1912–8.PubMedCrossRef Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood. 2019;134(22):1912–8.PubMedCrossRef
62.
Zurück zum Zitat Jones ME, Saleem A. Acute promyelocytic leukemia. A review of literature. Am J Med. 1978;65(4):673–7.PubMedCrossRef Jones ME, Saleem A. Acute promyelocytic leukemia. A review of literature. Am J Med. 1978;65(4):673–7.PubMedCrossRef
63.
Zurück zum Zitat Avvisati G, Lo Coco F, Mandelli F. Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors. Semin Hematol. 2001;38(1):4–12.PubMedCrossRef Avvisati G, Lo Coco F, Mandelli F. Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors. Semin Hematol. 2001;38(1):4–12.PubMedCrossRef
64.
Zurück zum Zitat Kuchenbauer F, Buske C. Revisiting thrombocytopenia in acute promyelocytic leukemia. Leukemia. 2018;32(6):1477–8.PubMedCrossRef Kuchenbauer F, Buske C. Revisiting thrombocytopenia in acute promyelocytic leukemia. Leukemia. 2018;32(6):1477–8.PubMedCrossRef
65.
Zurück zum Zitat Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013;37(9):1004–9.PubMedCrossRef Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013;37(9):1004–9.PubMedCrossRef
66.
Zurück zum Zitat Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75(11):2112–7.PubMedCrossRef Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75(11):2112–7.PubMedCrossRef
67.
Zurück zum Zitat Song YH, Peng P, Qiao C, Zhang R, Li JY, Lu H. Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia. Onco Targets Ther. 2017;10:4917–24.PubMedPubMedCentralCrossRef Song YH, Peng P, Qiao C, Zhang R, Li JY, Lu H. Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia. Onco Targets Ther. 2017;10:4917–24.PubMedPubMedCentralCrossRef
68.
Zurück zum Zitat Minamiguchi H, Fujita H, Atsuta Y, Asou N, Sakura T, Ueda Y, et al. Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia. Ann Hematol. 2020;99(12):2787–800.PubMedCrossRef Minamiguchi H, Fujita H, Atsuta Y, Asou N, Sakura T, Ueda Y, et al. Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia. Ann Hematol. 2020;99(12):2787–800.PubMedCrossRef
69.
Zurück zum Zitat Kim DY, Lee JH, Lee JH, Kim SD, Lim SN, Choi Y, et al. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. Leuk Res. 2011;35(2):152–8.PubMedCrossRef Kim DY, Lee JH, Lee JH, Kim SD, Lim SN, Choi Y, et al. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. Leuk Res. 2011;35(2):152–8.PubMedCrossRef
70.
Zurück zum Zitat Mitrovic M, Suvajdzic N, Bogdanovic A, Kurtovic NK, Sretenovic A, Elezovic I, et al. International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation >/= 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol. 2013;30(1):478.PubMedCrossRef Mitrovic M, Suvajdzic N, Bogdanovic A, Kurtovic NK, Sretenovic A, Elezovic I, et al. International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation >/= 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol. 2013;30(1):478.PubMedCrossRef
71.
Zurück zum Zitat de la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395–402.PubMedCrossRef de la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395–402.PubMedCrossRef
72.
Zurück zum Zitat Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017;129(13):1763–7.PubMedPubMedCentralCrossRef Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017;129(13):1763–7.PubMedPubMedCentralCrossRef
Metadaten
Titel
Dysregulated hemostasis in acute promyelocytic leukemia
verfasst von
Yohei Hisada
Publikationsdatum
11.02.2024
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Hematology
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-024-03708-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.